Related Experiment Video
Updated: Jun 5, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience
R F Saidi1, S A Shah, A P Rawson
1Division of Organ Transplantation, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. reza.saidi@umassmemorial.org
Abstract:
Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.
